Skip to content

Exploring the antitumor activity of curcumin in breast cancer

Exploring the antitumor activity of curcumin in the treatment of breast-cancer patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20131017015044N4
Enrollment
60
Registered
2020-01-23
Start date
2019-12-22
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast of unspecified site

Interventions

Intervention 1: Intervention group: Curcumin along with standard regime will be assigned to intervention group. The daily dose of crocin will be 80 mg during 24 weeks. Intervention 2: Control group:

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with metastatic breast cancer that is measurable Breast cancer patients who have not received any chemotherapy for metastasis patients at the age of 25 to 70

Exclusion criteria

Exclusion criteria: History of any allergy to turmeric or its products

Design outcomes

Primary

MeasureTime frame
Overall survival. Timepoint: One year after the treatment is completed. Method of measurement: Patient follow-up.

Secondary

MeasureTime frame
Progression-free survival. Timepoint: During treatment and after it every 3 months. Method of measurement: criteria of Response evaluation criteria in solid tumors.;Anemia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Neutropenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Thrombocytopenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Kidney function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of BUN and creatinine.;Liver function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of SGOT and SGPT.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodabeh Shahidsales

Mashhad University of Medical Sciences

Shahidsaless@mums.ac.ir+98 51 3846 1518

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026